Kymera Therapeutics Reports Strong Q1 Revenue Growth, $45M Gilead Milestone, and Positive Pipeline Updates

summarizeSummary

Kymera Therapeutics announced strong Q1 2026 financial results, including a 55.6% revenue increase, a $45 million milestone payment from Gilead, and FDA Fast Track designation for its KT-621 asthma program, while reaffirming its cash runway into 2029.

check_boxKey Events

• Strong Q1 Collaboration Revenue Growth

  Collaboration revenues increased by 55.6% year-over-year to $34.4 million for the first quarter of 2026, primarily from the Gilead Sciences partnership.

• Gilead Exercises Option for KT-200, Triggers $45M Milestone

  Gilead Sciences exercised its option to exclusively license KT-200, a CDK2 molecular glue degrader, resulting in a $45 million milestone payment to Kymera.

• KT-621 Receives FDA Fast Track for Asthma

  The U.S. Food and Drug Administration granted Fast Track designation to KT-621 for the treatment of moderate to severe eosinophilic asthma, adding to its prior Fast Track for atopic dermatitis.

• Reaffirms Cash Runway into 2029

  Kymera reported $1.55 billion in cash, cash equivalents, and investments as of March 31, 2026, extending its expected cash runway into 2029.

auto_awesomeAnalysis

Kymera Therapeutics reported robust first-quarter results, highlighted by a significant 55.6% year-over-year increase in collaboration revenue, driven by its partnership with Gilead Sciences. The company also announced that Gilead exercised its option to exclusively license KT-200, a CDK2 degrader, triggering a $45 million milestone payment. This non-dilutive cash inflow, combined with a reaffirmed cash runway into 2029, strengthens the company's financial position. Additionally, the FDA granted Fast Track designation to KT-621 for moderate to severe asthma, signaling positive regulatory progress for a key pipeline asset. These developments collectively present a positive outlook for Kymera's financial health and pipeline advancement.